Allogene Therapeutics Inc (NYSE:ALLO) Q1 2020 Earnings Conference Call - Final Transcript
May 06, 2020 • 08:30 am ET
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Allogene Therapeutics First Quarter 2020 Conference Call. [Operator Instructions] Please be aware that today's conference call is being recorded.
I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Thank you, operator. And good morning. We appreciate you joining us today and sincerely hope you are all doing well.
Before market opened today, Allogene issued a press release that provides a corporate update and financial results for the first quarter ended March 31, 2020. This press release is available on our website at www.allogene.com. We remind listeners that today's call is being webcast on our website and will be available for replay.
Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.
Please note that we are conducting our call today from different locations. So, we appreciate your patience and understanding should we have any technical difficulties.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities and 2020 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. These statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2019, our Form 8-K filed on March 27, 2020, as well as our upcoming Form 10-Q for the quarter ended March 31, 2020. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.
I'll now turn the call over to Dr. David Chang.
Thank you, Christine. Good morning, everyone. And thank you for taking time to join us for our first quarter conference call. It has been just over two months since our last earnings call, but the world seems a different place.
We hope you and your loved ones are safe and well. Our sincerest thanks to many of you who have reached out to ask about Arie Belldegrun after he announced that he has tested positive for COVID-19. We all feel very fortunate that his symptoms were relatively mild and he has fully recovered. At the same time, we are profoundly sorry about how the current dynamic has claimed so many lives and created hardship for everyone globally.
Across our industry, it is inspiring to see the way in which our scientific and regulatory communities have joined together to identify potential treatments and hopefully, a vaccine. The pharmaceutical and biotech industry are in